MediciNova Announces Publication of MN-166 (Ibudilast) Data on Using This Small Molecule to Inhibit Macrophage Migration Inhibitory Factor (MIF) Carried in Uveal Melanoma Exosomes and to Thereby Prevent Metastasis in Animal Model of Uveal Melanoma

On April 20, 2022, MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced data demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) animal model. This was published in Molecular Cancer Research. The article is titled “Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment Through Macrophage Migration Inhibitory Factor.”